Built in public. Updated as the evidence changes.

The evidence layer is operating

Search the public COA corpus, inspect vendor histories, compare observed prices and stock, look up a peptide batch, read sourced community reviews, submit a lab report, use the citation-first assistant, or route an eligible order with buyer protection. These are customer-visible products today, not roadmap promises.

Map the supply chain behind the vendor names

We are connecting the evidence buyers currently have to reconstruct for themselves. Every relationship should remain explainable: what matched, where it came from, when it was observed and how much confidence it deserves.

• A public supplier-network map linking upstream vendors, resellers, warehouses and shared infrastructure.
• Stronger batch discovery using product codes, dates, dose, cap color, packaging and source documents together.
• Review intelligence organized by source, sentiment, shipping, packaging, communication and resolution.
• More lab and community sources, with identity repair when a COA names the tester or reseller instead of the upstream supplier.

Turn continuous monitoring into useful decisions

Move from finding evidence manually to knowing when the evidence changed. The sequence will be driven by measured customer use and data quality, not a ceremonial launch date.

• Faster, more precise watchlist alerts for new COAs, inventory changes, price movement and material vendor-risk events.
• Shareable comparisons and evidence bundles that preserve the source record without rebuilding the research.
• Deeper domestic-warehouse and delivery-lane coverage across Australia, Canada, the UK and Europe.
• Governed exports and API workflows for research groups, clinics, resellers and other market operators.